Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 2.0 | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.04 | 1.93 |
NAV | ₹19.27 | ₹37.09 |
Fund Started | 06 Oct 2020 | 25 Jun 2018 |
Fund Size | ₹152.78 Cr | ₹4917.81 Cr |
Exit Load | - | Exit load of 1% if redeemed within 15 days. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 13.38% | 24.36% |
3 Year | 16.14% | 23.17% |
5 Year | - | 27.42% |
1 Year
3 Year
5 Year
Equity | 99.71% | 98.07% |
Cash | 0.17% | 1.93% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 12.37% |
Max Healthcare Institute Ltd. | 6.10% |
Cipla Ltd. | 5.74% |
Eli Lilly And Co | 5.61% |
Dr. Reddy's Laboratories Ltd. | 5.26% |
Apollo Hospitals Enterprise Ltd. | 5.07% |
Divi's Laboratories Ltd. | 4.93% |
Lupin Ltd. | 3.51% |
Johnson & Johnson Ltd. | 3.13% |
AbbVie Inc | 2.78% |
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 13.83% |
Cipla Ltd. | 9.28% |
Dr. Reddy's Laboratories Ltd. | 8.93% |
Divi's Laboratories Ltd. | 5.56% |
Aurobindo Pharma Ltd. | 5.05% |
Lupin Ltd. | 4.67% |
Alkem Laboratories Ltd. | 3.98% |
Gland Pharma Ltd. | 3.73% |
Mankind Pharma Ltd. | 3.22% |
Zydus Lifesciences Ltd. | 2.96% |
Name | Bhavesh Jain | Dharmesh Kakkad |
Start Date | 05 Jun 2023 | 23 Feb 2021 |
Name
Start Date
Description | The scheme seeks to invest in stocks comprising of the MSCI India Domestic & World Healthcare 45 Index with the objective to provide investment returns that, before expenses, closely corresponds to the returns equivalent to the index, subject to tracking errors. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 06 Oct 2020 | 25 Jun 2018 |
Description
Launch Date